Literature DB >> 2453881

Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein.

F X Real1, K S Furukawa, M J Mattes, S A Gusik, C Cordon-Cardo, H F Oettgen, L J Old, K O Lloyd.   

Abstract

Antibodies present in the serum of melanoma patient FD detect an antigenic determinant (FD) restricted to the autologous melanoma cell line SK-MEL-131. This cell-surface determinant is carried on a glycoprotein of 90 kDa, designated gp90. Mice were immunized with a partially purified preparation of gp90 derived from SK-MEL-131 clone 1.5, and three murine hybridomas (KF23, KF26, and KF104) secreting monoclonal antibodies (mAbs) detecting this antigen have been generated. Sequential immunoprecipitation experiments demonstrate that the three mAbs and human FD serum react with the same gp90 species. The mAbs, in contrast to FD serum, react with a broad range of cultured cells in assays for cell-surface antigens and immunoprecipitate a gp90 component from radiolabeled extracts of these cells, including autologous FD B cells. We conclude that gp90 from SK-MEL-131 has two types of determinants: restricted (detected by FD serum) and common (detected by the mouse mAbs). gp90 molecules from cell lines other than SK-MEL-131 carry only the common determinant(s). Immunoperoxidase analysis of frozen tissue sections with mAb KF23 demonstrated a restricted gp90 expression in normal tissues (capillary endothelial cells, duct epithelium in sweat glands, breast, and pancreas). Melanomas and sarcomas showed strong gp90 expression, suggesting up-regulation of gp90 synthesis in certain human cancers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453881      PMCID: PMC280341          DOI: 10.1073/pnas.85.11.3965

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Class 1 (unique) tumor antigens of human melanoma: partial purification and characterization of the FD antigen and analysis of a mouse polyclonal antiserum.

Authors:  M J Mattes; F X Real; K Furukawa; L J Old; K O Lloyd
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.

Authors:  T E Carey; K O Lloyd; T Takahashi; L R Travassos; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

4.  Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines.

Authors:  R F Irie; L L Sze; R E Saxton
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

5.  Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

Authors:  L D Cahan; R F Irie; R Singh; A Cassidenti; J C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

Review 6.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors:  L J Old
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

7.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

8.  Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.

Authors:  A P Albino; K O Lloyd; A N Houghton; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

9.  Human melanoma antigen AH is an autoantigenic ganglioside related to GD2.

Authors:  T Watanabe; C S Pukel; H Takeyama; K O Lloyd; H Shiku; L T Li; L R Travassos; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

10.  Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.

Authors:  A N Houghton; H Brooks; R J Cote; M C Taormina; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  6 in total

1.  Endo-beta-D-glucuronidase (heparanase) activity of heat-shock protein/tumour rejection antigen gp96.

Authors:  P K Srivastava
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

2.  Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract.

Authors:  S Parkkila; A Waheed; R S Britton; J N Feder; Z Tsuchihashi; R C Schatzman; B R Bacon; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

3.  Tumour rejection antigens of the hsp90 family (gp96) closely resemble tumour-associated heparanase enzymes.

Authors:  L D Graham
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

4.  Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins.

Authors:  R G Maki; L J Old; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  A unique antigenic epitope of human melanoma is carried on the common melanoma glycoprotein gp95/p97.

Authors:  K S Furukawa; K Furukawa; F X Real; L J Old; K O Lloyd
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

6.  A novel iron uptake mechanism mediated by GPI-anchored human p97.

Authors:  M L Kennard; D R Richardson; R Gabathuler; P Ponka; W A Jefferies
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.